<DOC>
	<DOCNO>NCT02008552</DOCNO>
	<brief_summary>More 5 million person France expose , last year , take Benfluorex . Arisen , certain patient , valvulopathy characterize mitrals and/or aortic leak Withdrawal French market : nov. 2009 Only percentage limit exposed patient develop severe valvulopathy ( 1/1000 ) , whereas contrary , many patient exposed year without develop slight anomaly . The hypothesis existence particular genetic susceptibility patient develop valvulopathy continuation exposure medicine . Existence one vary genetics strong effect . The purpose identify involve genetic factor .</brief_summary>
	<brief_title>Study Effect Benfluorex</brief_title>
	<detailed_description />
	<mesh_term>Benfluorex</mesh_term>
	<criteria>Inclusion Criteria case : Individual present typical medicinal valvulopathy define : A previous exposure least 6 month benfluorex occasional exposure accept posology . The preliminary exposure dexfenfluramine fenfluramine authorize . A picture board insufficiency mitral restrictive and/or aortic restrictive ( echocardiography ) typical medicinal achievement , gravity ( rank I IV ) , without cause associate valvulopathy compatible macroscopic histological aspect ( operated patient ) . Individual follow one site study recruit via association AVIM CADUS . Individual Caucasian origin Individual sign form specific consent study individual . Inclusion criteria witness : Individual presenting exposure previous benfluorex superior equal equivalent 2 year treatment 3 tablet day pursue 2 year precede realization cardiac echography screening . The preliminary exposure dexfenfluramine fenfluramine authorize . Individual present strictly normal cardiac echography particular : absence valvulopathy significant , morphological valvular anomaly ( event without echography ) valvular , include `` trivial '' leak aortic level . The mitrals micro leak `` physiological '' accept . Individual see screen one sit study French firm cardilogie cardiologists member French Society Cardiologyor include forwardlooking study coordinate Pr . TRIBOUILLOY ( objective compare echography data group patient treat least 3 month benfluorex group patient diabetic never receive medicine ) . Individual Caucasian origin . Individual sign form specific consent study Exclusion criterion case : Individual present another associate heart disorder . Individual expose another agonist receivers 5HT2B pergolide , cabergoline , lisuride , quibble byproduct ecstasy . Individual explicitly refuse participate study . Exclusion criteria witness : Individual explicitly refuse participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Genetic factor</keyword>
	<keyword>Valvulopathy</keyword>
	<keyword>Mediator</keyword>
</DOC>